SAFETY AND EFFICACY OF IPTACOPAN IN ADOLESCENT PATIENTS WITH IDIOPATHIC (PRIMARY) IMMUNE-COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)

https://storage.unitedwebnetwork.com/files/1099/024fe01af00007ffc712e8fbc9b1afb1.pdf
SAFETY AND EFFICACY OF IPTACOPAN IN ADOLESCENT PATIENTS WITH IDIOPATHIC (PRIMARY) IMMUNE-COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
Nicholas
Webb
David Kavanagh David.Kavanagh@newcastle.ac.uk Newcastle upon Tyne Hospitals NHS Foundation Trust National Renal Complement Therapeutics Centre Newcastle upon Tyne
Andrew S Bomback asb68@cumc.columbia.edu Columbia University College of Physicians and Surgeons Division of Nephrology New York
Richard J H Smith richard-smith@uiowa.edu Carver College of Medicine, University of Iowa Molecular Otolaryngology and Renal Research Laboratories and the Departments of Internal Medicine and Pediatrics Lowa City
UdayKiran Veldandi uday_kiran.veldandi@novartis.com Novartis HC Pvt Ltd Global Drug Development Hyderabad
Yaqin Wang yaqin.wang@novartis.com Novartis Pharmaceuticals Corporation Global Drug Development East Hanover, NJ
Matthias Meier matthias.meier@novartis.com Novartis Pharma AG Global Drug Development Basel
Marina Vivarelli marina.vivarelli@opbg.net Bambino Gesù Children's Hospital Division of Nephrology and Dialysis, Department of Pediatric Subspecialties Rome